OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.
2013 ◽
Vol 31
(15_suppl)
◽
pp. LBA9008-LBA9008
◽
Keyword(s):
Gm Csf
◽
LBA9008 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Saturday, June, 1, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.
2014 ◽
Vol 32
(15_suppl)
◽
pp. 9008a-9008a
◽
1998 ◽
Vol 16
(9)
◽
pp. 2930-2936
◽
1995 ◽
Vol 13
(7)
◽
pp. 1632-1641
◽
2012 ◽
Vol 30
(15_suppl)
◽
pp. CRA1002-CRA1002
◽
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA5002-LBA5002
◽
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA3500-LBA3500
Keyword(s):